Logo Image
|Articles|February 13, 2023

Novavax COVID Vaccine 140 Million Dose Order Canceled by Japan, Takeda Reveals

In 2021, Takeda announced a partnership with Novavax to manufacture 150 million doses of the Nuvaxovid COVID-19 vaccine; however, the Japanese government has canceled its order for the remaining 141.76 million doses due to low demand.

Japan's cancellation of the Novavax vaccine order will not significantly impact Takeda's finances and the company is not altering its full-year consolidated forecasts.

Related to this article

View more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: FDA Approves Welireg Plus Lenvima
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
Read more
Pharmaceutical executive daily
Pharmaceutical Executive Daily: FDA Approves Onswik
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.
Read more